Hypopharyngeal cysts are benign lesions of the upper aerodigestive tract, but their location makes them disproportionately dangerous. The hypopharynx sits immediately behind the larynx, and in young children the supraglottic airway is only millimeters wide. A cyst that would be a harmless curiosity in an adult can encroach on that slender channel with alarming speed. Reported lesions in this region include retention cysts, ductal cysts, foregut duplication cysts, bronchogenic cysts, and other epithelial-lined structures, each with distinct embryological origins but a shared capacity for airway compromise. Small cysts are usually asymptomatic; larger ones typically announce themselves gradually with stridor, feeding difficulties, dysphagia, voice changes, or recurrent respiratory infections.

What makes this case striking is the absence of any such warning signs. According to the clinical team, the child had been entirely well the previous evening. On the morning of presentation she developed breathing difficulty and throat pain, accompanied by a low-grade fever that was never formally documented. There was no history of foreign body aspiration, no prior episodes of stridor or dysphonia, no swallowing problems, and no recurrent chest infections. On examination she was alert, pink, and hemodynamically stable, with a patent airway at rest—but dynamic inspection of the oropharynx revealed a translucent, smooth, bulging lesion that became visible in the posterior pharyngeal wall during swallowing, hinting at positional variability that would prove mechanistically important.

Flexible nasopharyngolaryngoscopy provided the pivotal diagnostic clue. The endoscope showed a well-defined, translucent, fluid-filled cystic mass situated directly above the laryngeal inlet, narrowing the supraglottic airway while leaving the overlying mucosa intact. Dynamic assessment confirmed preserved vocal cord mobility, an important finding that argued against invasive or malignant disease. The precise anatomical origin of the cyst—whether from the hypopharyngeal wall, the posterior surface of the epiglottis, or an adjacent mucosal fold—could not be pinned down at the bedside, a limitation imposed by the child’s age and limited cooperation. That uncertainty made cross-sectional imaging essential before any surgical planning could proceed.

Contrast-enhanced computed tomography of the neck delivered three decisive pieces of information. First, it characterized the lesion: a homogeneously hypodense, thin-walled cyst approximately two centimeters in greatest diameter, without internal enhancement, septations, solid components, or calcifications—imaging features classic for a benign epithelial or retention cyst. Second, it mapped the anatomy, showing anterior displacement of the supraglottic structures with narrowing of the airway lumen and confirming the lesion’s extrinsic relationship to the laryngeal framework across multiplanar reformats. Third, it excluded alternatives with far more complex surgical implications, including vascular malformations, thyroglossal duct cysts, and malignancy. No lymphadenopathy or bony abnormality was identified.

With the diagnosis provisionally established, a multidisciplinary team of pediatric emergency physicians and otolaryngologists opted for temporizing conservative management rather than emergency surgery. The child was admitted for close airway monitoring and placed in the lateral decubitus position—a deceptively simple intervention with a sound biomechanical rationale. In the supine position, gravity pulls a hypopharyngeal lesion directly over the laryngeal inlet, a phenomenon well documented in the vallecular cyst literature; lateral positioning reduces that gravitational vector toward the glottis. She was kept nil per os in anticipation of surgery and received intravenous dexamethasone to reduce peri-lesional mucosal edema, nebulized adrenaline to attenuate airway swelling, and nebulized budesonide as an adjunctive anti-inflammatory agent. Throughout the observation period she remained stable, with no deterioration in respiratory status.

The following day, surgeons performed complete transoral excision under general anesthesia. With the neck extended to optimize laryngoscopic access and pharyngeal packing in place to protect the lower airway, direct laryngoscopy revealed the cystic mass nestled between the base of the tongue and the posterior tonsillar pillar region. The lesion was well encapsulated with a smooth outer surface and, critically, was removed intact with cold instruments—without entry into the cyst cavity. Complete removal of the entire cyst wall is the surgical goal in such cases, because residual epithelial lining is the principal substrate for recurrence. The child remained vitally stable throughout the procedure.

Histopathology settled the question of what the cyst actually was. The excised specimen, measuring approximately 2.5 by 2 centimeters, showed a wall of fibrovascular connective tissue infiltrated by reactive inflammatory cells. The lining was a mosaic: non-keratinized stratified squamous epithelium in some areas and respiratory-type columnar epithelium in others, a pattern consistent with a simple epithelial cyst arising at the transitional zones where these two mucosal types meet physiologically in the hypopharynx. No cytological atypia, dysplasia, or malignancy was found, and cytology of the cyst fluid showed only reactive inflammatory and scattered squamous cells. The inflammatory infiltrate within the wall also lent support to an intriguing hypothesis about why the lesion decompensated so abruptly: retention cysts may enlarge acutely when inflammation obstructs their drainage orifice, a mechanism analogous to an acutely infected epidermal inclusion cyst. That would explain how a lesion that presumably existed quietly for some time could suddenly threaten the airway after a trivial febrile illness.

The recovery was uneventful. The child tolerated oral fluids, progressed to a soft diet, and was discharged on oral antibiotics. At follow-up two weeks later she was entirely well, and at five months she remained asymptomatic with no evidence of recurrence. The authors acknowledge the limits of that follow-up window—five months cannot speak to very long-term recurrence rates—and note that the precise developmental origin of the cyst, whether from minor salivary gland tissue, respiratory epithelial rests, or obstructed mucosal glands, cannot be determined with certainty from the histology alone. They also emphasize that the entire evidence base for pediatric hypopharyngeal cysts rests on isolated case reports and small series, which constrains how far generalizable recommendations can stretch.

The broader lesson is one of diagnostic humility in pediatric airway emergencies. Children presenting with apparent croup or acute epiglottitis who fail to respond as expected to conventional pharmacotherapy should prompt consideration of a cystic lesion, the authors argue, particularly when the onset is abrupt in a child with no antecedent airway history. The case also illustrates a rational division of labor between diagnostic tools: flexible endoscopy for immediate, dynamic, bedside characterization of the lesion and its effect on the airway, and contrast-enhanced CT for anatomical mapping, benignity assessment, and exclusion of dangerous mimics—provided the child is stable enough to undergo scanning. When conservative positional and pharmacological measures can temporize the obstruction, surgery can be elective rather than desperate, and complete transoral excision under general anesthesia remains safe, technically feasible, and curative in the majority of reported cases. For clinicians, the message is that even a lesion with no warning signs at all can sit silently above a toddler’s vocal cords until the night it suddenly does not.

Subject of Research: A pediatric case of acute airway obstruction caused by a rare simple epithelial hypopharyngeal cyst, diagnosed with endoscopy and CT and treated by transoral excision.

Article Title: Simple Epithelial Hypopharyngeal Cyst Presenting as Acute Airway Obstruction in a Three‐Year‐Old Child: A Case Report and Literature Review

Article References: Noori, F., Salahat, S., Salous, A., Thabet, T. M., Nazzal, K., & Daghlas, A. (2026). Simple Epithelial Hypopharyngeal Cyst Presenting as Acute Airway Obstruction in a Three‐Year‐Old Child: A Case Report and Literature Review. Clinical Case Reports, 14(10), Article e73666. https://doi.org/10.1002/ccr3.73666

Image Credits: AI Generated

DOI: 10.1002/ccr3.73666

Keywords: hypopharyngeal cyst, pediatric airway obstruction, stridor, nasopharyngolaryngoscopy, contrast-enhanced CT, transoral excision, supraglottic lesion, retention cyst, histopathology, otolaryngology, case report, airway management

The researchers built a cyber-physical framework anchored in Internet of Things sensing at the bedside. The system continuously acquires and fuses four fundamentally different kinds of clinical data: ventilator waveform parameters that describe the mechanics of each delivered breath, diaphragm ultrasound imaging features that reveal whether the patient’s principal breathing muscle is strong enough to sustain independent ventilation, arterial blood gas indices that capture the adequacy of oxygenation and carbon dioxide clearance, and static patient baseline profiles such as demographics and comorbidity information. Each of these streams has its own sampling rate, dimensionality, and noise characteristics. The framework therefore employs a gated recurrent architecture—a class of neural network designed to carry relevant information across time steps while discarding noise—augmented by a cross-modal attention mechanism. In practical terms, attention allows the model, at every moment, to decide which data stream deserves the most weight: when the ventilator waveform shows rapid shallow breathing, the model may attend more strongly to respiratory mechanics; when the waveform looks stable but the diaphragm ultrasound shows thinning muscle, the imaging signal can dominate the assessment.

On top of this multimodal perception layer sits the decision-making core, and here the study makes a choice that reflects a hard lesson learned across the field of medical artificial intelligence. Rather than training a reinforcement learning agent by trial and error in a live clinical environment—an approach that would be ethically untenable, since an exploring algorithm might deliberately test suboptimal ventilator settings on real patients—the team used offline reinforcement learning. The specific algorithm, Conservative Q-Learning, learns a dynamic ventilation parameter adjustment policy entirely from retrospective data. Its defining trick is conservatism: the agent learns the value of actions that appear in the historical record, but it systematically penalizes the estimated value of out-of-distribution actions that the dataset never demonstrates. This prevents the classic failure mode of offline reinforcement learning, in which an agent extrapolates confidently about actions no clinician ever took and recommends them with unwarranted certainty. The result is a policy that can suggest how ventilation parameters might be adjusted over time while remaining anchored to what experienced clinicians actually did, and to the outcomes that followed.

Complementing the policy agent, the framework includes a discrete-time survival model that produces calibrated, uncertainty-aware estimates of each individual patient’s probability of successful weaning. This is a critical piece of clinical trustworthiness. A single point prediction—say, a 78 percent chance of weaning success—tells a clinician little about how confident the model really is. By working in discrete time steps and reporting uncertainty, the survival model tells the care team not only what the system expects but how much the system itself doubts that expectation, allowing human judgment to calibrate accordingly. The pairing of a reinforcement learning policy with an uncertainty-aware probabilistic forecast reflects a broader trend in clinical machine learning: decision support systems are increasingly designed to quantify their own limitations rather than present deceptively crisp answers.

The privacy architecture is where the study pushes furthest beyond conventional clinical prediction models. Hospitals are naturally reluctant to pool intensive care data, which is among the most sensitive health information that exists, and legal frameworks in many jurisdictions restrict or complicate cross-institution data sharing. The researchers therefore adopted a federated learning protocol based on FedProx, an algorithm in which each participating hospital trains the model locally on its own patients and shares only model parameter updates—never raw data—with a coordinating server. FedProx adds a proximal term that keeps each hospital’s local model from drifting too far from the global consensus, a safeguard that matters in clinical settings where different units see different patient mixes and hardware varies. On top of federation, the framework applies Gaussian differential privacy with a privacy budget of epsilon equal to 1.0, a mathematically rigorous guarantee that the contribution of any single patient’s record to the learned model is bounded and quantifiable. A privacy budget of 1.0 is a meaningfully strict setting; it trades some statistical efficiency for a strong formal assurance that no individual’s ventilator traces, imaging studies, or blood gas values can be reconstructed from the shared model updates.

Recognizing that no two hospitals are identical, the team also incorporated MAML-style local personalization, drawing on the Model-Agnostic Meta-Learning paradigm. MAML trains a model not to perform a single task well but to be rapidly adaptable, so that each participating otolaryngology or head and neck surgery unit can fine-tune the shared model to its own patient population with minimal local data. This addresses a persistent tension in federated medical AI: a single global model may average away the very idiosyncrasies that matter for a specialized unit, while fully independent local models sacrifice the statistical power of pooled learning. Meta-learned personalization offers a middle path—the global model learns how to learn, and each site adapts quickly.

The evaluation was substantial. The team trained and tested the framework on 36,181 weaning episodes drawn from two widely used critical care databases, MIMIC-IV and eICU-CRD, which together capture thousands of intensive care stays from multiple hospitals. Performance was measured with the area under the receiver operating characteristic curve, or AUROC, a standard metric of discriminative ability in which 0.5 represents chance and 1.0 represents perfect separation of outcomes. On internal validation the system achieved an AUROC of 0.893, and on external validation—testing on data the model had not been tuned against—it reached 0.871. The modest drop between the two figures is itself informative, suggesting the model generalizes rather than memorizes. Perhaps most striking for privacy-minded readers, the federated variant of the system narrowed the performance gap to fully centralized training to within 0.001 AUROC. In other words, the hospitals could, in principle, learn together across institutional boundaries with almost no measurable cost in predictive accuracy, while keeping every raw record inside its originating institution and carrying a formal differential privacy guarantee.

The clinical target of the work deserves emphasis. Airway liberation—deciding when a patient can safely breathe without mechanical support—is particularly fraught in otolaryngological practice. After head and neck surgery, swelling, surgical anatomy, and impaired laryngeal function can make the airway fragile in ways that routine weaning parameters, which were largely validated on cardiac and general medical ICU populations, do not capture. Diaphragm ultrasound adds a direct window into respiratory muscle readiness, ventilator waveforms expose the pattern of patient-ventilator interaction, and blood gases confirm physiological stability, but integrating these heterogeneous signals in real time has traditionally been a matter of clinical intuition. The framework described in the study formalizes that integration, turning four bedside data streams into a continuously updated, uncertainty-aware estimate of weaning readiness, alongside a policy that indicates how ventilation might be adjusted as the patient progresses.

It is worth noting what the study does and does not claim. The system was evaluated on retrospective databases, not deployed prospectively at the bedside, and the authors report that the research received no dedicated funding and that the authors declare no competing financial interests. The work was published open access on 4 September 2026 in Complex & Intelligent Systems, a peer-reviewed journal, and carries the DOI 10.1007/s40747-026-02488-w. Retrospective validation is the necessary first step in the long path toward clinical deployment, which would require prospective trials, regulatory review, and integration with hospital information systems. But the architectural choices—offline learning that never experiments on patients, federated training that never moves raw data, differential privacy that bounds individual leakage, and uncertainty quantification that flags the model’s own doubt—are precisely the design patterns that regulators and clinicians have been demanding from medical AI.

The broader significance of the study lies in its demonstration that privacy and performance need not be opposing forces in clinical intelligence. For years, the assumption in health data science was that the price of protecting patient privacy was a meaningful loss of model accuracy, and that institutions would have to choose between collaborative learning and competitive performance. By combining IoT-scale multimodal sensing, conservative offline reinforcement learning, federated optimization with personalization, and formal privacy guarantees—and by showing that the federated system trails centralized training by less than a thousandth of an AUROC point—the Shanghai team has offered a concrete existence proof that this trade-off can be nearly eliminated. If subsequent prospective studies confirm the retrospective results, the framework could point the way toward a generation of hospital AI that learns from every patient it serves without ever requiring any single patient’s data to leave the ward.

Subject of Research: A privacy-preserving federated IoT and offline reinforcement learning framework for predicting mechanical ventilation weaning in patients with upper airway pathology

Article Title: Privacy-preserving federated IoT intelligence for multimodal airway liberation decision support via offline reinforcement learning

Article References: Privacy-preserving federated IoT intelligence for multimodal airway liberation decision support via offline reinforcement learning. (n.d.). https://doi.org/10.1007/s40747-026-02488-w

Image Credits: AI Generated

DOI: 10.1007/s40747-026-02488-w

Keywords: mechanical ventilation weaning, federated learning, offline reinforcement learning, Internet of Things, differential privacy, clinical decision support, diaphragm ultrasound, MIMIC-IV, airway management, conservative Q-learning, multimodal data fusion, otolaryngology

The molecule in question is maresin 1, or MaR1, a specialized pro-resolving mediator derived from docosahexaenoic acid, the omega-3 fatty acid abundant in fish oil. Specialized pro-resolving mediators were discovered relatively recently in the history of inflammation research, and they overturned a long-standing assumption that the end of an inflammatory response was simply a passive winding down. Instead, scientists led by Charles Serhan and colleagues showed that resolution is an active, orchestrated program, driven by lipid signals such as resolvins, protectins and maresins that recruit the cells needed to clear debris, quieten immune signaling and restore tissue. Maresin 1, produced by macrophages, has attracted particular attention because it both curbs inflammatory signaling and supports tissue regeneration. The question the Turkish team asked was deceptively simple: if MaR1 is the body’s own inflammation terminator, what is it doing in nasal polyps, where inflammation clearly refuses to resolve?

To find out, the researchers, led by Zulkuf Kaya of the Department of Ear, Nose and Throat Diseases at Atatürk University Research Hospital in Erzurum, together with pharmacologists from Atatürk University and Erzincan Binali Yıldırım University, recruited 60 patients. Thirty of them were undergoing endoscopic sinus surgery for nasal polyps, while the other 30, scheduled for rhinoplasty, served as controls and provided healthy nasal mucosa samples. The design is a straightforward case-control comparison, but it gives researchers a rare window into the biochemistry of polyp tissue at the moment it is removed. The work was approved by the Atatürk University Faculty of Medicine Clinical Research Ethics Committee and conducted with written informed consent from all participants, in line with the Declaration of Helsinki.

From each tissue sample the team measured the concentrations of three molecules using enzyme-linked immunosorbent assay, or ELISA, a technique that uses antibodies to quantify specific proteins with high sensitivity. Alongside MaR1, they measured transforming growth factor beta, TGF-β, a cytokine long implicated in tissue remodeling, fibrosis and the chronic wound-like state of polyp tissue, and nuclear factor erythroid 2–related factor 2, Nrf2, the master transcriptional regulator of the cellular antioxidant response. The choice of these three targets reflects a growing view in the field that nasal polyps are not merely an allergic or infectious problem, but a systems-level failure involving oxidative stress, unresolved inflammation and disordered tissue repair.

The results were striking. In the polyp group, the researchers observed that levels of both MaR1 and Nrf2 were significantly increased compared with healthy nasal mucosa, while TGF-β levels were significantly decreased. At first glance, the direction of these changes may seem counterintuitive. If MaR1 resolves inflammation and Nrf2 defends against oxidative damage, why would both be elevated in a tissue that is famously inflamed? The authors suggest that the answer lies in the dynamics of a chronic inflammatory process: the body may be mounting a compensatory response, ramping up its pro-resolving and antioxidant machinery in an attempt to contain the damage, even as the underlying drivers of inflammation persist and overwhelm it.

This interpretation fits with what is known about the biology of each player. Nrf2 normally sits dormant in the cytoplasm, bound to its inhibitor Keap1, until reactive oxygen species or electrophilic stress liberate it to travel to the nucleus and switch on a battery of antioxidant and detoxifying genes. In chronically inflamed tissues, sustained oxidative stress would be expected to activate Nrf2 persistently, and elevated levels have been reported in a range of inflammatory airway diseases. Similarly, TGF-β is a double-edged cytokine: it drives fibrosis and epithelial remodeling, processes central to polyp growth, but its measured abundance in tissue can vary with the stage of disease, the cellular composition of the sample and the interplay with other signaling pathways. A significant decrease in TGF-β in polyp tissue, as observed here, invites questions about how the remodeling program in polyps is regulated and how it might interact with the pro-resolving lipid pathways the team set out to study.

The study’s real contribution may lie in connecting these threads. By measuring MaR1 alongside Nrf2 and TGF-β in the same samples, the researchers have, for the first time in this tissue, laid out a triad of signals that could plausibly form an intracellular circuit: lipid-mediated resolution signals, antioxidant transcriptional responses and profibrotic cytokine activity, all shifting together in polyp pathophysiology. If future work confirms functional links between them, for example whether MaR1 signaling influences Nrf2 activation or modulates TGF-β-driven fibrosis in airway epithelial cells and macrophages, it would open a genuinely new therapeutic axis. Current treatments for nasal polyps, from intranasal and systemic corticosteroids to the newer biologics targeting type 2 inflammation, such as dupilumab, address specific arms of the immune response but do not directly harness the body’s own resolution program.

The idea of resolution-based therapy is one of the more exciting frontiers in inflammation medicine. Animal studies have shown that maresin 1 and related mediators can reduce tissue damage in models ranging from colitis to lung injury, and stable synthetic analogs are being explored as drug candidates. If the elevation of MaR1 in polyp tissue reflects a genuine, if insufficient, attempt at self-resolution, then supplementing that signal, perhaps with inhaled or topical formulations, could in principle help tip the balance from chronic inflammation back toward tissue homeostasis. Conversely, the altered TGF-β profile suggests that any such approach would need to account for the remodeling biology of polyps, not just the inflammatory one. The authors themselves are careful on this point, noting that potential treatments for nasal polyps may be better understood with more comprehensive and well-matched studies.

That caution is warranted. The study is a cross-sectional comparison of tissue removed at surgery, so it captures a snapshot rather than a trajectory, and it cannot establish whether the changes in MaR1, Nrf2 and TGF-β are causes or consequences of polyp formation. The control group, drawn from rhinoplasty patients, is a reasonable comparator but may differ from the polyp group in ways beyond the presence of polyps. ELISA measurements of lipid mediators in tissue are also technically demanding, and the field has learned that careful validation is essential. The authors acknowledge that larger and better-matched cohorts will be needed before the findings can guide clinical decisions. Still, the study was peer-reviewed and published open access in BMC Pharmacology and Toxicology, with the accepted manuscript released in September 2026, and it was supported by Atatürk University’s Scientific Research Projects Coordination Unit.

For patients, the significance of this work is less about immediate new treatments and more about a shift in perspective. Nasal polyps have long been treated as a problem of too much inflammation; this study reframes them, at least in part, as a problem of failed resolution, in which the body’s own peacekeeping molecules are present but apparently not prevailing. Mapping how maresin 1, Nrf2 and TGF-β interact inside the cells of the nasal mucosa could eventually point to biomarkers that identify which patients are most likely to recur after surgery, or to drugs that restore the resolution program the tissue is struggling to complete. The sense of smell, the ability to breathe freely through the nose, and freedom from a cycle of steroids and repeat operations all hang on that molecular balance. This study does not settle it, but it draws the map with considerably more detail than before.

Subject of Research: The role of the pro-resolving lipid mediator maresin 1 and the Nrf2 and TGF-β pathways in nasal polyp pathophysiology

Article Title: Investigation of maresin 1 and possible associated intracellular pathways in nasal polyp pathophysiology

Article References: Kaya, Z., Mutlu, V., Halici, Z., Kaya, Z. K., Ozcelik, A. T., Topatan, E., & Ozcelik, C. (2026). Investigation of maresin 1 and possible associated intracellular pathways in nasal polyp pathophysiology. BMC Pharmacology and Toxicology. https://doi.org/10.1186/s40360-026-01242-9

Image Credits: AI Generated

DOI: 10.1186/s40360-026-01242-9

Keywords: maresin 1, nasal polyps, Nrf2, TGF-β, inflammation resolution, specialized pro-resolving mediators, docosahexaenoic acid, ELISA, chronic rhinosinusitis, oxidative stress, otolaryngology, BMC Pharmacology and Toxicology

Vocal fold paralysis occurs when the nerves supplying the vocal folds, most commonly the recurrent laryngeal nerve, are damaged or dysfunctional, leaving one or both folds unable to move properly. The condition is far more often unilateral than bilateral, and the two presentations pose fundamentally different clinical problems. Patients with unilateral vocal fold paralysis typically struggle with a breathy, weak voice, difficulty swallowing, and an elevated risk of aspiration because the paralyzed fold cannot close the glottis during speech or swallowing. Bilateral paralysis, by contrast, can be life-threatening: when both folds are immobile near the midline, the airway itself may be obstructed, sometimes constituting a surgical emergency. Most cases in adults follow iatrogenic injury during thyroid, cardiothoracic, or esophageal surgery, while malignancies of the lung and larynx, stroke, trauma, and idiopathic causes account for much of the remainder.

The therapeutic arsenal for these patients is broad and reflects the divergent goals of treatment. For unilateral paralysis, surgeons aim to reposition or bulk up the immobile fold so that it can meet its functioning partner. Temporary options include hyaluronic acid injection, while calcium hydroxylapatite provides medialization lasting roughly eighteen months on average and autologous fat around six to twelve months. When the glottal gap exceeds three millimeters, framework surgery such as type I thyroplasty, sometimes combined with arytenoid adduction, is generally preferred and achieves voice improvement in eighty to ninety percent of cases. Laryngeal reinnervation, which reroutes nerve supply such as the ansa cervicalis to the recurrent laryngeal nerve, does not restore dynamic movement but improves static competence, muscle tone, and long-term stability by preventing denervation atrophy. For bilateral paralysis, the priority shifts to enlarging the airway through posterior cordotomy, partial or subtotal arytenoidectomy, or cordectomy, procedures that achieve decannulation rates of eighty-seven to one hundred percent among tracheostomized patients, albeit with substantial revision needs.

Despite the maturity of these techniques, the evidence base for their safety has remained surprisingly thin. Most published series are small, single-center studies drawn from homogeneous patient populations, leaving clinicians without reliable, generalizable estimates of perioperative risk. The new analysis was designed to close that gap. The investigators queried the ACS-NSQIP database, a prospectively maintained registry that collects standardized perioperative data from more than six hundred participating hospitals, using diagnostic codes for vocal fold paralysis and paresis together with a comprehensive list of procedural codes covering injection laryngoplasty, framework surgery, glottis-enlarging procedures, and reinnervation. Complications were aggregated into composite outcomes: surgical complications such as infections, wound dehiscence, and bleeding; medical complications ranging from pneumonia and reintubation to stroke, cardiac arrest, and sepsis; and an overall composite that also included reoperation.

The resulting cohort closely mirrored the expected epidemiology of the disease. Of the 931 patients, 857, or ninety-two percent, had unilateral paralysis, while seventy-four, or eight percent, had bilateral disease. Mean age was about sixty years in both groups, body mass index averaged twenty-nine kilograms per square meter, and roughly fifty-five percent of patients were women, a balanced sex distribution the authors suggest may more accurately reflect the true epidemiology than the divergent ratios reported in smaller studies. The majority of patients in both groups were classified as American Society of Anesthesiologists class three, indicating severe systemic disease, underscoring that these procedures are routinely performed in medically complex individuals. Most operations, around ninety percent in each group, were completed on an outpatient basis, with mean operative times of roughly one hundred minutes.

The safety outcomes were remarkably consistent across the two diagnostic groups. The overall complication rate was 3.4 percent for unilateral cases and 2.7 percent for bilateral cases, a difference that was not statistically significant. Reoperation was required in 0.93 percent of unilateral and 1.4 percent of bilateral patients, while surgical complications occurred at nearly identical rates of about 1.5 percent in both groups. Medical complications arose in 1.4 percent of unilateral cases and none of the bilateral cases. There were no significant between-group differences in superficial or deep infections, organ space infection, wound dehiscence, bleeding, pneumonia, reintubation, prolonged ventilation, urinary tract infection, stroke, cardiac arrest, myocardial infarction, deep vein thrombosis, sepsis, or septic shock. Notably, the analysis recorded no cases of sepsis, septic shock, or organ-space infection at all, findings the authors interpret as validation of established perioperative safety protocols.

The single patient who required ventilation beyond forty-eight hours illustrates how baseline frailty, rather than the procedure itself, can drive adverse outcomes. The individual was an eighty-year-old, ASA class three patient with congestive heart failure and hypertension who experienced a cascade of postoperative events including unplanned reintubation, cardiopulmonary resuscitation, blood transfusion, reoperation, and prolonged ventilation. Although no causal inference can be drawn from a single observation, the case highlights the importance of preoperative risk stratification in this population. This concern is particularly relevant given the burden of chronic pulmonary disease in the cohort: 8.1 percent of patients had chronic obstructive pulmonary disease, yet only six cases of pneumonia, or 0.64 percent, and a single reintubation, or 0.11 percent, were observed across the entire study period, figures consistent with or better than historical single-center series.

These results arrive amid ongoing debate about the optimal timing of surgery. Because spontaneous recovery occurs in a meaningful fraction of patients, with reported remission rates for idiopathic unilateral paralysis ranging from thirty to sixty-nine percent and most evidence clustering near the lower end, guidelines generally recommend deferring definitive procedures such as injection glottoplasty or type I thyroplasty for at least six and ideally up to twelve months. Prolonged denervation, however, causes progressive atrophy of the intrinsic laryngeal muscles that can compromise eventual functional outcomes, and significant aspiration or threatened airway protection may justify earlier temporary augmentation. Currently, no diagnostic marker reliably distinguishes patients who will recover spontaneously from those who will need surgery, forcing clinicians to balance the window for neural recovery against the risk of irreversible muscular deterioration on a case-by-case basis.

The authors are careful to frame the study as a measure of safety rather than efficacy. The ACS-NSQIP database captures only thirty days of follow-up, so long-term outcomes such as sustained voice quality, swallowing function, and airway stability fall outside its scope. Nor does the registry provide granular detail on specific techniques, primary versus revision procedures, or the underlying etiology of paralysis, and the binary structure of its outcome variables may underrepresent subtler morbidities like persistent dysphonia or delayed aspiration recovery. Because the database largely reflects North American practice, the findings may not generalize fully to international settings. Nevertheless, by transcending the single-center biases that have limited prior work, the analysis establishes a dependable benchmark: thirty-day morbidity after vocal fold paralysis surgery is low, comparable between unilateral and bilateral disease, and low enough to reassure both surgeons and the patients they counsel.

Subject of Research: Thirty-day perioperative safety of surgical intervention for unilateral and bilateral vocal fold paralysis in a multicenter ACS-NSQIP cohort

Article Title: Thirty-day perioperative safety following surgical intervention for unilateral and bilateral vocal fold paralysis: a multicenter ACS-NSQIP analysis

Article References: Schaschinger, T., Hoch, C. C., Knoedler, L., Niederegger, T., Dyhr, W. J., Hundeshagen, G., Lellouch, A. G., Voss, L. J., & Voss, J. O. (2026). Thirty-day perioperative safety following surgical intervention for unilateral and bilateral vocal fold paralysis: a multicenter ACS-NSQIP analysis. BMC Plastic and Reconstructive Surgery, 2(1), Article 26. https://doi.org/10.1186/s44452-026-00039-3

Image Credits: AI Generated

DOI: 10.1186/s44452-026-00039-3

Keywords: vocal fold paralysis, ACS-NSQIP, perioperative safety, phonosurgery, thyroplasty, injection laryngoplasty, laryngeal reinnervation, bilateral vocal fold paralysis, unilateral vocal fold paralysis, surgical complications, otolaryngology, medialization